Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05311566

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Effectiveness and Safety of Camrelizumab Combined With Concurrent Chemoradiotherapy for FIGO IB2-IIIB Cervical Cancer: A Single-center, Single-arm, Open-phase II Clinical Study

Sponsor: Lei Li

Conditions Adverse Events Anti-programmed Cell Death Receptor 1 Cervical Carcinoma Chemoradiotherapy Early Stage Cervical Cancer Immune Checkpoint Inhibitor Immunotherapy Locally Advanced Cervical Cancer Survival Outcomes

Interventions Camrelizumab plus Concurrent chemoradiotherapy

Updated 3 times since 2022 Last updated: Apr 5, 2022 Started: Mar 27, 2022 Primary completion: Mar 27, 2023 Completion: Mar 27, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adverse Events and Anti-programmed Cell Death Receptor 1 and is currently actively recruiting participants. Lei Li leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2022 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China